FAQ: What the Expanded Marstacimab Approval Means for Hemophilia A, B

The US Food and Drug Administration (FDA) has expanded the approval of marstacimab-hncq (Hympavzi), widening the drug's use in hemophilia A and hemophilia B.¹ "A treatment that can reduce bleeding with straightforward, once-weekly administration has the potential to fundamentally change how patients and caregivers approach this disease," said Guy Young, MD, director of the Hemostasis and Thrombosis Center at Children's Hospital Los Angeles, in a statement.¹ Below, HCPLive answers what clinicians need to know about the expanded indication.